Short exposure and a small healthy-volunteer sample constrain a withdrawal conclusion.
A phase I study evaluated repeated PF-06372865 dosing over twenty-one days, including initial titration. Nineteen participants were assigned and eighteen completed treatment. Reported events were mild, and withdrawal symptoms were not observed after discontinuation.
The compound’s receptor profile differs from nonselective benzodiazepines. Limited duration, sample size and selected volunteers cannot exclude uncommon events, dependence after longer use or different outcomes in patients.
Report how long exposure lasted before citing the absence of withdrawal. Target engagement and tolerability do not establish long-term clinical benefit or class-wide safety. The study cannot show that a different GABA-directed medicine can be stopped without difficulty in an individual patient.
Source: PMC8359322, supplied full-text paper. Findings are paraphrased; forensic implications are an interpretation.
Related: A Portuguese Benzodiazepine-Dependence Questionnaire Was Validated in a Selected Population.